Anthony H Goldstone

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
    Bella Patel
    Department of Haematology, Royal Free and University College London Medical School, and BSBMT Data Registry, Guy s Hospital, London, UK
    Haematologica 94:1399-406. 2009
  2. ncbi request reprint In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/
    Anthony H Goldstone
    North London Cancer Network, University College London Hospitals, London, United Kingdom
    Blood 111:1827-33. 2008
  3. doi request reprint Transplantations in adult acute lymphoblastic leukemia--grounds for optimism?
    Anthony H Goldstone
    Department of Haematology, University College London Hospitals, London NW1 2BU, United Kingdom
    Clin Lymphoma Myeloma 9:S211-3. 2009
  4. pmc UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
    Adele K Fielding
    University College London, London, United Kingdom
    Blood 123:843-50. 2014
  5. ncbi request reprint High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    Adrian J C Bloor
    Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
    Biol Blood Marrow Transplant 14:50-8. 2008
  6. ncbi request reprint Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    Karl S Peggs
    Department of Haematology, Royal Free and University College, London, UK
    Br J Haematol 139:70-80. 2007
  7. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
  8. ncbi request reprint Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens
    Kirit M Ardeshna
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 130:363-72. 2005
  9. ncbi request reprint Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab
    Irit Avivi
    Department of Haematology, University College Hospital, London, UK
    Biol Blood Marrow Transplant 10:186-94. 2004
  10. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003

Detail Information

Publications47

  1. pmc Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
    Bella Patel
    Department of Haematology, Royal Free and University College London Medical School, and BSBMT Data Registry, Guy s Hospital, London, UK
    Haematologica 94:1399-406. 2009
    ..Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known...
  2. ncbi request reprint In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/
    Anthony H Goldstone
    North London Cancer Network, University College London Hospitals, London, United Kingdom
    Blood 111:1827-33. 2008
    ..There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514...
  3. doi request reprint Transplantations in adult acute lymphoblastic leukemia--grounds for optimism?
    Anthony H Goldstone
    Department of Haematology, University College London Hospitals, London NW1 2BU, United Kingdom
    Clin Lymphoma Myeloma 9:S211-3. 2009
    ..The youngest adults might not need to undergo transplantation at all. If they are now treated on pediatric chemotherapy protocols, their outcome appears to improve significantly...
  4. pmc UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
    Adele K Fielding
    University College London, London, United Kingdom
    Blood 123:843-50. 2014
    ..A proportion of the OS benefit derives from the fact that imatinib facilitates alloHSCT. This trial was registered at clinicaltrials.gov as NCT00002514. ..
  5. ncbi request reprint High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    Adrian J C Bloor
    Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
    Biol Blood Marrow Transplant 14:50-8. 2008
    ..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
  6. ncbi request reprint Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    Karl S Peggs
    Department of Haematology, Royal Free and University College, London, UK
    Br J Haematol 139:70-80. 2007
    ....
  7. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
    ....
  8. ncbi request reprint Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens
    Kirit M Ardeshna
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 130:363-72. 2005
    ..This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored...
  9. ncbi request reprint Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab
    Irit Avivi
    Department of Haematology, University College Hospital, London, UK
    Biol Blood Marrow Transplant 10:186-94. 2004
    ....
  10. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
    ..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
  11. ncbi request reprint High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
    Blood 99:4357-63. 2002
    ..The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis...
  12. ncbi request reprint Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University College Hospital, London, UK
    Br J Haematol 119:1125-32. 2002
    ....
  13. ncbi request reprint Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
    Stephen P Robinson
    Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, London, United Kingdom
    Blood 100:4310-6. 2002
    ..A longer period of follow-up is required to determine the benefit of DLI and the graft-versus-lymphoma effect...
  14. doi request reprint Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma
    Jonathan R Lambert
    Department of Haematology, University College London Cancer Institute, London, UK
    Blood 115:2763-8. 2010
    ....
  15. doi request reprint Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial
    Alan K Burnett
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
    J Clin Oncol 28:586-95. 2010
    ..To optimize treatment for younger patients with acute myeloid leukemia and high-risk myelodysplastic syndrome by comparing induction options and the number of consolidation courses and whether consolidation should include transplantation...
  16. doi request reprint Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
    Alan K Burnett
    Department of Haematology, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
    J Clin Oncol 29:369-77. 2011
    ..We previously established that it is feasible to combine GO with conventional chemotherapy. We now report a large randomized trial testing the addition of GO to induction and/or consolidation chemotherapy in untreated younger patients...
  17. doi request reprint Redefining transplant in acute leukemia
    Rob Sellar
    Department of Haematology, University College London Hospital, UK
    Curr Treat Options Oncol 12:312-28. 2011
    ..The importance of enrolling patients into suitable prospective clinical trials cannot be overstated...
  18. ncbi request reprint Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
    David Grimwade
    Department of Medical and Molecular Genetics, King s College London School of Medicine and Department of Haematology, Guy s and St Thomas NHS Foundation Trust, London, United Kingdom
    Blood 116:354-65. 2010
    ..This study is registered at http://www.isrctn.org as ISRCTN55678797 and ISRCTN17161961...
  19. doi request reprint Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL T
    Adele K Fielding
    University College London, London, United Kingdom
    Blood 113:4489-96. 2009
    ..This prospective trial in adult Ph(+) ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223...
  20. doi request reprint Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial
    Jonathan I Sive
    Department of Haematology, University College London Hospital, London
    Br J Haematol 157:463-71. 2012
    ..New approaches, including better risk stratification and use of targeted therapies, could improve treatment for these patients...
  21. doi request reprint Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning
    William M Townsend
    Department of Haematology, University College London Hospitals NHS Foundation Trust and UCL Medical School, London, UK
    Br J Haematol 161:578-86. 2013
    ..Reduced intensity Allo-HSCT patients admitted to ICU with critical illness have improved survival compared to myeloablative Allo-HSCT recipients...
  22. ncbi request reprint Long-term results of the MRC AML10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, United Kingdom
    Clin Adv Hematol Oncol 4:445-51. 2006
  23. ncbi request reprint Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
    Charalampia Kyriakou
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 129:763-70. 2005
    ..We conclude that the CDT regimen is safe, well tolerated and effective in patients with relapsed and refractory myeloma...
  24. ncbi request reprint Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection
    Karl S Peggs
    Department of Haematology, University College London, London, United Kingdom
    Biol Blood Marrow Transplant 9:198-205. 2003
    ....
  25. ncbi request reprint A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Alan K Burnett
    Department of Haematology, Wales School of Medicine, Cardiff University, Cardiff, United Kingdom
    Cancer 109:1114-24. 2007
    ..The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach...
  26. ncbi request reprint Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, London, UK
    Br J Haematol 125:756-65. 2004
    ..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome...
  27. doi request reprint Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993
    Bella Patel
    Department of Haematology, University College London Medical School, London
    Br J Haematol 148:80-9. 2010
    ..These data provide a rationale for introducing MRD-based risk stratification in future studies for the delineation of those at significant risk of treatment failure in whom intensification of therapy should be evaluated...
  28. ncbi request reprint Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure
    Jaimal Kothari
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 165:334-40. 2014
    ..Our data shows that BEAM ASCT can be a highly effective treatment in patients with FL early in the disease course, and that a proportion of patients experience prolonged disease-free survival and may be cured...
  29. doi request reprint Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience
    Jonathan Sive
    Department of Haematology, University College London Hospital, London, UK
    Leuk Lymphoma 53:2397-404. 2012
    ..An ACU/hotel-based treatment model can be safely used for a wide variety of cancers and treatments, expanding hospital treatment capacity, and freeing up inpatient beds for those patients requiring them...
  30. doi request reprint Transplants in Adult ALL--? Allo for everyone
    Anthony H Goldstone
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 15:7-10. 2009
    ..If they are now treated on pediatric chemotherapy protocols, their outcome appears to improve significantly. The MRC/ECOG study, the emerging MUD and RIC data all help establish allogeneic transplant more widely in this disease...
  31. ncbi request reprint Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
    Ronjon Chakraverty
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 99:1071-8. 2002
    ..In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation...
  32. pmc Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol
    Marc R Mansour
    Department of Haematology, University College London, UCL Cancer Institute, WC1E 6BT, United Kingdom
    J Clin Oncol 27:4352-6. 2009
    ..We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol...
  33. ncbi request reprint Conventional allograft and autograft in low grade lymphoma
    Irit Avivi
    Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, P O Box 9602, Haifa 31096, Israel
    Best Pract Res Clin Haematol 18:113-28. 2005
    ..However, data is still limited and follow-up in the majority of studies is relatively short, highlighting the need for longer follow-up to establish the role of reduced intensity SCT in low grade lymphoma...
  34. ncbi request reprint Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries
    Elisabeth Vandenberghe
    Department of Haematology, St James Hospital, Dublin, Ireland
    Br J Haematol 120:793-800. 2003
    ..99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR...
  35. ncbi request reprint The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial
    Alan K Burnett
    Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, Wales, UK
    Br J Haematol 118:385-400. 2002
    ..This trial found no survival advantage in children, patients over 35 years or good-risk disease...
  36. ncbi request reprint Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
    Katharine Branson
    CR UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 20:4022-31. 2002
    ..The aim of the current study was to evaluate the safety and efficacy of sibling, HLA-matched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoid malignancy after failure of autologous SCT...
  37. ncbi request reprint Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
    Norbert Schmitz
    Department of Internal Medicine II, University of Kiel, Kiel, Germany
    Lancet 359:2065-71. 2002
    ..We aimed to compare this treatment with conventional aggressive chemotherapy without stem-cell transplantation (Dexa-BEAM)...
  38. ncbi request reprint Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
    Jacob M Rowe
    Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel
    Blood 106:3760-7. 2005
    ..However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor...
  39. ncbi request reprint Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
    Jose A Perez-Simon
    Department of Hematology, Hospital Universitairo de Salamanca, Paseo de San Vicente s n, 37007 Salamanca, Spain
    Blood 100:3121-7. 2002
    ..Patients receiving alemtuzumab often required DLIs to achieve similar tumor control but the incidence of GVHD was not significantly increased after DLI...
  40. ncbi request reprint Development of squamous cell carcinoma of the skin during induction chemotherapy for acute myeloid leukemia
    Panagiotis D Kottaridis
    Leuk Lymphoma 43:459-60. 2002
  41. ncbi request reprint Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
    Emma C Morris
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
    Blood 102:404-6. 2003
    ..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
  42. ncbi request reprint Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia
    Christine J Harrison
    Leukaemia Research Fund Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton, UK
    Br J Haematol 125:552-9. 2004
    ..Thus cytogenetics, or at least a clear definition of the modal chromosome number, is essential at diagnosis in order to stratify patients with hypodiploidy into the appropriate risk group for treatment...
  43. ncbi request reprint The allogeneic effect in non-Hodgkin's lymphoma
    Anthony H Goldstone
    North London Cancer Network, 6th Floor, Rosenheim Wing, 25 Grafton Way, London WC1E 6DB, UK
    Leuk Lymphoma 44:S91-7. 2003
    ..However, treatment will be improved by optimizating conditioning regimens and a better understanding of patient selection criteria and the immune processes involved in graft-vs.-host disease and GVT...
  44. ncbi request reprint Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    Karl S Peggs
    Department of Haematology, Royal Free and University College London, UK
    Lancet 365:1934-41. 2005
    ..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
  45. ncbi request reprint Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
    Adele K Fielding
    Royal Free and University College London Medical School, and Christie Hospital National Health Service Trust, Manchester, UK
    Blood 109:944-50. 2007
    ..Prevention of recurrence is the best strategy for long-term survival in this disease...
  46. ncbi request reprint Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias
    Dejan Juric
    Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
    J Clin Oncol 25:1341-9. 2007
    ..To identify gene expression patterns and interaction networks related to BCR-ABL status and clinical outcome in adults with acute lymphoblastic leukemia (ALL)...
  47. ncbi request reprint Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
    Anthony V Moorman
    Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, UK
    Blood 109:3189-97. 2007
    ....